Global Oncology Clinical Trials Market Projected to Reach US$ 25.61 Billion by 2035, Supported by Advances in Precision and Targeted Therapies Says Astute Analytica

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

• The number of oncology Novel Active Substances (NAS) launched globally in the 5-year period ending 2024 reached 132

  80% confidence

• Novel modalities, including ADCs and Cell/Gene therapies, accounted for 35% of all oncology trial starts in 2024

  80% confidence

• The global oncology clinical trials market is projected to hit the market valuation of USD 25.61 billion by 2035 from USD 14.95 billion in 2025 at a CAGR of 5.53% during the forecast period 2026–2035

  80% confidence

• Asia-Pacific is projected to witness the fastest CAGR from 2025 to 2034

  80% confidence

• The probability of technical success for ADC monotherapies in Phase III is 53%, higher than the general oncology average

  80% confidence

• A 160% increase in pancreatic cancer survival rates was reported in 2024 due to clinical trial advancements

  80% confidence

• Biosimilars in oncology generated USD 7 billion in savings for payers in 2023/2024, with cumulative savings reaching USD 19 billion since 2017

  80% confidence

• Spending on cancer medicines will reach USD 441 billion by 2029

  80% confidence

• 2,162 oncology clinical trials were initiated globally in 2024, representing a 12-unit increase on an index basis compared to 2019 levels

  80% confidence

• Global spending on cancer medicines reached USD 252 billion in 2024, reflecting a USD 29 billion increase from the previous year

  80% confidence

• North America accounted for over 41.58% revenue share of the oncology clinical trials market

  80% confidence

Data points we hold from this source